What would you sell it for if you owned it now? If it goes down after you buy would you sell or buy more? At what prices? Now ask yourself yourself if this is a good entry point.
bought the pullback and sold calls hoping I could buy them back cheap and add more. Just barely got them back without taking a loss. Bullish flag printing.
I think somebody brought another database server up and had the wrong character set configured for it.
I was just looking at this from a technical standpoint. The reverse split caused shorts to close out their positions and was a big factor in the run up to 55. So they re entered short and have chased it down here twice over the last few years. From the long term support in the 14-15 dollar area and the stock trading at that level when citadel shut the door with the first shelf it seems to me this would be a good price to be covering in. It should trade in a dollar range 15.50 -16.50 for several weeks while shorts take profit. Any weak handed longs should have stopped out by now so they have to rely on long bottom feeders to take profit to provide the liquidity. I donu0027t know if the bottom is in yet or not but I seriously doubt there are shorts that expect the company to go bankrupt so they never have to cover. So if not now, when? I wonu0027t buy more unless it goes well into 14u0027s but will sell in the 16.80 area.
early to call, but the setup is there to print a bullish flag. Needs to consolidate more up here for another leg up.
dont forget the progressive weight gain caused by steroids. Also keep in mind the small N. High variability should be expected. Could even bounce back up if one kid gets better.
One of the characteristics of successful people is the ability to maneuver and change tactically while remaining steadfast in the pursuit of a dream.
Will/have they obtained all the patients so the testing results can be time aligned? If so that would mean they are all in the dosing phase.
I have to wonder what's really going on. Making money in small cap biotech isn't all about the value proposition. In the last reporting period institutional ownership declined 5% and produced a 7 dollar decline in stock price.In this period certain hedge funds opened new positions and added to existing ones. Presumably whoever has been buying is also shorting the stock. From the subsequent price decay I think it is reasonable to surmise that this trend is continuing into this quarter. Somebody is strategically accumulating the stock while forcing sales to create liquidity at bargain prices. At some price an equilibrium should establish as new buyers with longer horizons come in and the short sellers lighten up on the short side to take profit. I don't see any strong technical support levels down here so this is really a question about when the sun will come out again.
good question. Two companies come to mind that set some precedence. DNDN's provenge apparently does not provide enough palliation (bang for the buck). On the other hand ITMN esbriet appears to provide enough to be a commercial success. From what I know of these 2 products it seems that 3 months is not enough extra life but 6 months is. Eteplirsen appears to be in the years category. There's a difference in that in the case of MD diagnosis can be made well before symptoms appear and could be much more beneficial than the results seen in the clinical trials.
I don't see the connection here.Although certain bashers do seem to have uncanny clairvoyance wrt FDA pronouncements.